Truvian Health recently announced an injection of USD$74 million of capital to be used in part to secure US Food and Drug Administration (FDA) clearance for its blood testing platform.

Truvian’s automated benchtop platform enables simple, accurate, and comprehensive routine blood tests to be performed in clinics, doctor’s offices and pharmacies. Over the past twelve months, Truvian has presented data from multiple independent clinical studies demonstrating that results from its platform are equivalent to those produced in a central laboratory across a large panel of tests.

Planet Innovation is Truvian’s development and manufacturing partner for its automated benchtop platform. Truvian and Planet Innovation exhibited together at ADLM2024 in Chicago, the largest clinical diagnostics conference of the year. ADLM (Association for Diagnostics & Laboratory Medicine) was formerly known as AACC.